The TLR7 agonist induces tumor regression both by promoting CD4+T cells proliferation and by reversing T regulatory cellmediated suppression via dendritic cells

Oncotarget

Volumn 6, Issue 3, 2015, Pages 1779-1789

  Wang, Chenchen ^a   Zhou, Quan ^a   Wang, Xiaofeng ^a   Wu, Xiongyan ^a   Chen, Xuehua ^a   Li, Jianfang ^a   Zhu, Zhenggang ^a   Liu, Bingya ^a   Su, Liping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Anti tumor effect; Immune suppression; TLR7; Treg cells

Indexed keywords

ANTINEOPLASTIC AGENT; IMIQUIMOD; INTERLEUKIN 6; LIGAND; LOXORIBIN; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 7 AGONIST; UNCLASSIFIED DRUG; GUANOSINE; LOXORIBINE; MEMBRANE PROTEIN; TLR7 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; COLON CANCER; DENDRITIC CELL; DRUG INDICATION; DRUG MECHANISM; EFFECTOR CELL; FOOD AND DRUG ADMINISTRATION; IMMUNE DEFICIENCY; IMMUNOSURVEILLANCE; IN VIVO STUDY; LEWIS CARCINOMA; LUNG CANCER; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SKIN CANCER; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR REGRESSION; TUMOR XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CARCINOMA, LEWIS LUNG; COLONIC NEOPLASMS; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; PROCEDURES; SCID MOUSE;

ANIMALS; CARCINOMA, LEWIS LUNG; CD4-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; DENDRITIC CELLS; GUANOSINE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 7;

EID: 84922736400     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2757     Document Type: Article

References (49)

1. Von Scheidt B, Leung PS, Yong MC, Zhang Y, Towne JE, Smyth MJ, Teng MW. Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. Cancer Res. 2014; 74:2412-2421.
2. Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol. 2014; 44:1582-1592.
3. Wang D, DuBois RN. Myeloid-derived suppressor cells link inflammation to cancer. Oncoimmunology. 2014; 3:e28581.
4. Cuenca AG, Cuenca AL, Winfield RD, Joiner DN, Gentile L, Delano MJ, Kelly-Scumpia KM, Scumpia PO, Matheny MK, Scarpace PJ, Vila L, Efron PA, LaFace DM, Moldawer LL. Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia. J Immunol. 2014; 192:6111-6119.
5. Lutsiak ME, Tagaya Y, Adams AJ, Schlom J, Sabzevari H. Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J Immunol. 2008; 180:5871-5881.
6. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. Regulatory CD4+CD25+T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001; 61:4766-4772.
7. Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004; 20:107-118.
8. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) toxin to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005; 28:582-592.
9. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005; 115:3623-3633.
10. Wang RF. Regulatory T cells and toll-like receptors in cancer therapy. Cancer Res. 2006; 66:4987-4990.
11. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004; 5:987-995.
12. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004; 4:499-511.
13. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol. 2001; 31:3388-3393.
14. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001; 194:863-869.
15. Liu G, Zhao Y. Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+T cells. Immunology. 2007; 122:149-156.
16. Schenten D, Nish SA, Yu S, Yan X, Lee HK, Brodsky I, Pasman L, Yordy B, Wunderlich FT, Bruning JC, Zhao H, Medzhitov R. Signaling through the adaptor molecule MyD88 in CD4+T cells is required to overcome suppression by regulatory T cells. Immunity. 2014; 40:78-90.
17. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997; 388:394-397.
18. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol. 2005; 560:11-18.
19. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+T cell-mediated suppression by dendritic cells. Science. 2003; 299:1033-1036.
20. Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol. 2006; 27:387-393.
21. Sutmuller R, Garritsen A, Adema GJ. Regulatory T cells and toll-like receptors: regulating the regulators. Ann Rheum Dis. 2007; 66:iii91-95.
22. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2006; 103:7048-7053.
23. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY, Wang RF. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science. 2005; 309:1380-1384.
24. Gupta AK, Cherman AM, Tyring SK. Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg. 2004; 8:338-352.
25. Soong RS, Song L, Trieu J, Knoff J, He L, Tsai YC, Huh W, Chang YN, Cheng WF, Roden RB, Wu TC, Trimble CL, Hung CF. Toll like receptor agonist imiquimod facilitates antigen-specific CD8+T cell accumulation in the genital tract leading to tumor control through interferon-gamma. Clin Cancer Res. 2014; 20:5456-67.
26. Huang SJ, Hijnen D, Murphy GF, Kupper TS, Calarese AW, Mollet IG, Schanbacher CF, Miller DM, Schmults CD, Clark RA. Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009; 129:2676-2685.
27. Zhang Y, Luo F, Cai Y, Liu N, Wang L, Xu D, Chu Y. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol. 2011; 186:1963-1969.
28. van Maren WW, Jacobs JF, de Vries IJ, Nierkens S, Adema GJ. Toll-like receptor signalling on Tregs: to suppress or not to suppress?. Immunology. 2008; 124:445-452.
29. Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, Illidge TM, Murata M, Robinson DT, Jewsbury PJ, Wilkinson RW, Stratford IJ. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Int J Cancer. 2014; 135:820-829.
30. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2013; 2:e25238.
31. Larange A, Antonios D, Pallardy M, Kerdine-Romer S. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J Leukoc Biol. 2009; 85:673-683.
32. Pircher A, Gamerith G, Amann A, Reinold S, Popper H, Gachter A, Pall G, Woll E, Jamnig H, Gastl G, Wolf AM, Hilbe W, Wolf D. Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients. Lung cancer. 2014; 85:81-87.
33. Rooney CM. Can Treg elimination enhance NK cell therapy for AML? Blood. 2014; 123:3848-3849.
34. Akbari A, Rezaei A. In vitro selective depletion of CD4+CD25+ regulatory T-cells from PBMC using antitac-SAP. J Immunotoxicol. 2012; 9:368-373.
35. Li X, Kostareli E, Suffner J, Garbi N, Hammerling GJ. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur J Immunol. 2010; 40:3325-3335.
36. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J, Sparwasser T. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010; 70:7788-7799.
37. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 2007; 67:371-380.
38. Voo KS, Bover L, Harline ML, Weng J, Sugimoto N, Liu YJ. Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells. J Immunol. 2014; 193:627-634.
39. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, Berzofsky JA. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest. 2010; 120:607-616.
40. He C, Chen M, Liu J, Yuan Y. Host genetic factors respond to pathogenic step-specific virulence factors of Helicobacter pylori in gastric carcinogenesis. Mutat Res Rev Mutat Res. 2014; 759C:14-26.
41. Okeke EB, Okwor I, Uzonna JE. Regulatory T cells restrain CD4+T cells from causing unregulated immune activation and hypersensitivity to lipopolysaccharide challenge. J Immunol. 2014; 193:655-662.
42. Nyirenda MH, Sanvito L, Darlington PJ, O'Brien K, Zhang GX, Constantinescu CS, Bar-Or A, Gran B. TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol. 2011; 187:2278-2290.
43. Van Maren WW, Nierkens S, Toonen LW, Bolscher JM, Sutmuller RP, Adema GJ. Multifaceted effects of synthetic TLR2 ligand and Legionella pneumophilia on Treg-mediated suppression of T cell activation. BMC Immunol. 2011; 12:23.
44. Fang H, Ang B, Xu X, Huang X, Wu Y, Sun Y, Wang W, Li N, Cao X, Wan T. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell Mol Immunol. 2014; 11:150-159.
45. Mandraju R, Murray S, Forman J, Pasare C. Differential ability of surface and endosomal TLRs to induce CD8 T cell responses in vivo. J Immunol. 2014; 192:4303-4315.
46. Kubo T, Hatton RD, Oliver J, Liu X, Elson CO, Weaver CT. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunology. 2004; 173:7249-7258.
47. Tel J, Sittig SP, Blom RA, Cruz LJ, Schreibelt G, Figdor CG, de Vries IJ. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen crosspresentation and robust type I IFN secretion. J Immunol. 2013; 191:5005-5012.
48. Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, Storch B, Sandholzer N, Wurzenberger C, Anz D, Endres S. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res. 2011; 71:5123-5133.
49. Hackl D, Loschko J, Sparwasser T, Reindl W, Krug AB. Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. Eur J Immunol. 2011; 41:1334-1343.